7 Indian firms in race, experts eye cheaper Keytruda version in 2 years

With at least seven Indian manufacturers in the race to develop generic versions of Merck & Co’s best-selling cancer immunotherapy drug Keytruda, doctors and researchers say a far cheaper alternative could be available within two years when the drug’s patent expires in June 2028 — offering hope at a time when each mandated 200mg dose […]